History of the AIDS Crisis: A Timeline

The AIDS crisis emerged in the early 1980s as a mysterious and terrifying disease that affected various communities and defied medical understanding of the time. What began as isolated reports of rare infections quickly grew into a global outbreak that claimed millions of lives and exposed deep social and political divides. Yet, out of fear and loss came extraordinary activism, compassion, and scientific discovery. Over the decades, relentless research has turned despair into hope, transforming HIV/AIDS from a fatal illness into a manageable chronic condition. The timeline below presents defining moments that have shaped the ongoing fight against AIDS.

Emergence and recognition

• 1981: The U.S. Centers for Disease Control and Prevention (CDC) reports rare cases of Pneumocystis pneumonia and Kaposi sarcoma in young gay men in Los Angeles, New York City, and San Francisco—the first recognized cases of what would later be known as AIDS.
• 1982: The term AIDS, short for acquired immunodeficiency syndrome, is formally adopted by the CDC.
• 1983: Scientists at the Pasteur Institute in France, led by Luc Montagnier and Françoise Barré-Sinoussi, identify a new retrovirus—eventually named human immunodeficiency virus, or HIV—as the likely cause of AIDS.
• 1984: American virologist Robert Gallo confirms that the virus, which he refers to as human T-lymphotropic retrovirus III (HTLV-III; later HIV), causes AIDS.

A deepening crisis

• 1985: The first blood test to detect HIV is approved by the U.S. Food and Drug Administration (FDA), enabling screening of blood supplies and diagnosis of infection. Actor Rock Hudson’s death from AIDS-related complications raises public awareness of the disease.
• 1986: Ryan White, an American teenager with hemophilia who developed AIDS after receiving a contaminated blood transfusion, is granted legal permission to return to school. He was barred from attending in person because of widespread fear that his illness could be contagious. White’s case draws attention to the need to educate the public about AIDS.
• 1987: The FDA approves the antiretroviral drug AZT (zidovudine), making it the first medication available to combat HIV. Activist group ACT UP (AIDS Coalition to Unleash Power) is founded to demand faster drug approval and better care.
• 1988: The World Health Organization (WHO) establishes World AIDS Day (December 1) to raise global awareness.
• 1989: Reports confirm drug resistance to AZT, which highlights a need for combination therapy.

Scientific progress and advocacy

• 1991: The red ribbon is adopted worldwide as a symbol of solidarity and awareness in the fight against AIDS.
• 1994: Antiretroviral therapy (ART), specifically AZT, is found to dramatically reduce mother-to-child transmission of HIV when taken during pregnancy.
• 1995–96: Introduction of highly active antiretroviral therapy (HAART)—a combination of drugs targeting HIV at multiple stages—transforms HIV/AIDS from a fatal disease into a manageable chronic condition.
• 1996: A new joint program, UNAIDS, is formed to organize and strengthen the worldwide response to the AIDS crisis.
• 1998: The U.S. Department of Health and Human Services issues a statement about nonoccupational post-exposure prophylaxis (PEP)—the first formal guidelines regarding the use of ART following possible HIV exposure outside a health care or occupational setting.

Expanding treatment and global action

• 2003: The U.S. launches the President’s Emergency Plan for AIDS Relief (PEPFAR), which will provide large-scale funding for HIV/AIDS treatment and prevention in low-income countries.
• 2007: The number of people living with HIV who receive ART reaches almost three million worldwide, marking a major step forward for WHO’s “3 by 5” initiative, which had aimed to provide treatment to that number of affected individuals in low- and middle-income countries by 2005.
• 2010: ART is shown to be highly effective in reducing the risk of sexual HIV transmission, which reinforces the idea of “treatment as prevention.”

Prevention and ongoing progress

• 2012: Truvada, a combination of the antiretroviral drugs tenofovir disoproxil fumarate and emtricitabine, becomes the first medication cleared by the FDA for pre-exposure prophylaxis (PrEP). When used alongside safer-sex practices, Truvada can help high-risk individuals lower their chances of contracting HIV.
• 2016: The United Nations announces a global objective to end the AIDS crisis by 2030.
• 2017–22: Initial studies show that long-acting antiretroviral injections and simplified regimens can improve ART adherence.
• 2021: Arpetude (cabotegravir) is approved by the FDA as the first extended-release injectable option for HIV prevention. Clinical trials have demonstrated its superiority to daily oral PrEP in reducing HIV risk.
• 2024: Global deaths from HIV/AIDS-related diseases total about 630,000 for the year, which continues a downward trend begun in the mid-2000s. Nonetheless, disparities in access to care persist, particularly in sub-Saharan Africa.